CN111093658B - 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 - Google Patents

用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 Download PDF

Info

Publication number
CN111093658B
CN111093658B CN201880048242.4A CN201880048242A CN111093658B CN 111093658 B CN111093658 B CN 111093658B CN 201880048242 A CN201880048242 A CN 201880048242A CN 111093658 B CN111093658 B CN 111093658B
Authority
CN
China
Prior art keywords
formula
compound
alkyl
mek
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880048242.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111093658A (zh
Inventor
J·金凯德
M·邓克顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enfreixon Treatment Co ltd
Original Assignee
Enfreixon Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enfreixon Treatment Co ltd filed Critical Enfreixon Treatment Co ltd
Publication of CN111093658A publication Critical patent/CN111093658A/zh
Application granted granted Critical
Publication of CN111093658B publication Critical patent/CN111093658B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN201880048242.4A 2017-05-19 2018-05-18 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 Active CN111093658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US62/508,997 2017-05-19
PCT/US2018/033544 WO2018213807A1 (en) 2017-05-19 2018-05-18 Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Publications (2)

Publication Number Publication Date
CN111093658A CN111093658A (zh) 2020-05-01
CN111093658B true CN111093658B (zh) 2022-10-14

Family

ID=62620965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880048242.4A Active CN111093658B (zh) 2017-05-19 2018-05-18 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物

Country Status (13)

Country Link
US (2) US10988483B2 (https=)
EP (1) EP3624795B1 (https=)
JP (1) JP7237941B2 (https=)
KR (1) KR102659322B1 (https=)
CN (1) CN111093658B (https=)
AU (1) AU2018270292B2 (https=)
CA (1) CA3063535A1 (https=)
DK (1) DK3624795T3 (https=)
ES (1) ES2913213T3 (https=)
IL (1) IL270576B (https=)
MA (1) MA49140A (https=)
MX (1) MX2019013562A (https=)
WO (1) WO2018213807A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7237941B2 (ja) * 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
CA3120351A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP4233834A3 (en) * 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130160A2 (en) * 2004-07-23 2006-12-07 Amgen Inc. Furanopyridine derivatives as ack1 and lck modulators
WO2007088345A1 (en) * 2006-01-31 2007-08-09 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008024724A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
WO2009013462A1 (en) * 2007-07-23 2009-01-29 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP5710855B2 (ja) 2005-02-02 2015-04-30 ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 神経線維腫の局所治療
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
EP2089359A2 (en) 2006-10-31 2009-08-19 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
PE20081354A1 (es) 2006-11-30 2008-11-14 Genentech Inc Compuestos de azaindolilo como inhibidores de mek
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP2010043019A (ja) 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
WO2012040636A2 (en) 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
PT3624796T (pt) 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
JP7237941B2 (ja) 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130160A2 (en) * 2004-07-23 2006-12-07 Amgen Inc. Furanopyridine derivatives as ack1 and lck modulators
WO2007088345A1 (en) * 2006-01-31 2007-08-09 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008024724A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
WO2009013462A1 (en) * 2007-07-23 2009-01-29 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEK and the inhibitors:from bench to bedside;AKINTUNDE AKINLEYE等;《JOURNAL OF HEMATOLOGY & ONCOLOGY》;20130412;第6卷(第1期);第27页 *

Also Published As

Publication number Publication date
US11542271B2 (en) 2023-01-03
CA3063535A1 (en) 2018-11-22
US20210380601A1 (en) 2021-12-09
US10988483B2 (en) 2021-04-27
CN111093658A (zh) 2020-05-01
US20200172550A1 (en) 2020-06-04
MA49140A (fr) 2020-03-25
EP3624795B1 (en) 2022-04-20
IL270576B (en) 2022-01-01
EP3624795A1 (en) 2020-03-25
JP7237941B2 (ja) 2023-03-13
WO2018213807A1 (en) 2018-11-22
JP2020520994A (ja) 2020-07-16
KR20200026812A (ko) 2020-03-11
MX2019013562A (es) 2020-08-03
DK3624795T3 (da) 2022-05-23
ES2913213T3 (es) 2022-06-01
AU2018270292A1 (en) 2019-12-05
KR102659322B1 (ko) 2024-04-22
AU2018270292B2 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CN111065393B (zh) 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
CN111093658B (zh) 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
CN113473978B (zh) 用于治疗皮肤疾病氰基芳烃-苯胺化合物
CN113473986B (zh) 用于治疗皮肤疾病萘啶酮苯胺化合物
HK40026703A (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders
HK40026703B (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant